The feline MDR1 mutation (ABCB11930_1931delTC) has been associated with neurological toxicosis after topical application of eprinomectin products labeled for feline use. Information was collected from veterinarians who submitted samples for ABCB11930_1931delTC genotyping. In most cases, the submission form indicated an adverse event involving eprinomectin, in other cases submitting veterinarians were contacted to determine whether the patient had experienced an adverse drug event involving eprinomectin. If so, additional information was obtained to determine whether the case met inclusion criteria. 14 cases were highly consistent with eprinomectin toxicosis. Eight cats were homozygous for ABCB11930_1931del TC (3 died; 5 recovered). Six cats were homozygous wildtype (2 died; 4 recovered). The observed ABCB11930_1931delTC frequency (57%) was higher than the expected frequency (≤1%) in the feline population (Fisher Exact test, p < .0001). Among wildtype cats, four were concurrently treated with potential competitive inhibitors of P-glycoprotein. Results indicate that topical eprinomectin products, should be avoided in cats homozygous for ABCB11930_1931delTC. This is a serious, preventable adverse event occurring in an identifiable subpopulation treated with FDA-approved products in accordance with label directions. Acquired P-glycoprotein deficiency resulting from drug interactions may enhance susceptibility to eprinomectin-induced neurological toxicosis in any cat, regardless of ABCB1 genotype.

中文翻译：

---

以标签剂量使用含依立诺菌素的杀虫剂会导致 ABCB11930_1931del TC 纯合子猫神经中毒

猫科动物 MDR1 突变 ( ABCB1 1930_1931delTC) 与局部使用标有猫用标签的依立诺菌素产品后的神经中毒有关。信息是从提交样品进行ABCB1 1930_1931delTC 基因分型的兽医那里收集的。在大多数情况下，提交表格表明涉及依立诺菌素的不良事件，在其他情况下，我们会联系提交兽医以确定患者是否经历过涉及依立诺菌素的不良药物事件。如果是，则获得更多信息以确定该病例是否符合纳入标准。14例与依立诺菌素中毒高度一致。八只猫是ABCB1 1930_1931del TC 纯合子（3 只死亡；5 只康复）。六只猫是纯合野生型（2 只死亡；4 只康复）。观察到的ABCB1 1930_1931delTC 频率 (57%) 高于猫科动物群体中的预期频率 (≤1%)（Fisher 精确检验，p  < .0001）。在野生型猫中，有四只猫同时接受了潜在的 P-糖蛋白竞争性抑制剂治疗。结果表明，对于ABCB1 1930_1931delTC纯合子的猫，应避免使用局部依立诺菌素产品。这是一种严重的、可预防的不良事件，发生在按照标签说明使用 FDA 批准的产品治疗的可识别亚人群中。药物相互作用导致的获得性 P-糖蛋白缺乏可能会增加任何猫对依立诺菌素诱导的神经中毒的易感性，无论ABCB 1 基因型如何。